Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Open-label, Multicenter Study to Assess the Immunogenicity and Safety of GSK Meningococcal MenABCWY Vaccine, and of GSK Meningococcal Group B and MenACWY Conjugate Vaccines Administered Concomitantly in the Same Arm or in 2 Different Arms, or Alone in Healthy Subjects 10 to 25 Years of Age.

Trial Profile

A Phase II, Randomized, Open-label, Multicenter Study to Assess the Immunogenicity and Safety of GSK Meningococcal MenABCWY Vaccine, and of GSK Meningococcal Group B and MenACWY Conjugate Vaccines Administered Concomitantly in the Same Arm or in 2 Different Arms, or Alone in Healthy Subjects 10 to 25 Years of Age.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2018

At a glance

  • Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; Meningococcal vaccine groups A B C Y W-135 conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal infections
  • Focus Pharmacodynamics
  • Acronyms MENABCWY-016 (V102_19)
  • Sponsors GlaxoSmithKline Biologicals
  • Most Recent Events

    • 13 Sep 2018 Planned End Date changed from 4 Mar 2019 to 6 Dec 2018.
    • 13 Sep 2018 Planned primary completion date changed from 4 Mar 2019 to 6 Dec 2018.
    • 13 Sep 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top